Urinary incontinence aggravated in Vyvanse - how severe and when it was recovered? (a real world drug study)

Summary:

We study how severe was Urinary incontinence aggravated, when it was recovered, drug effectiveness, race, and more among people who take Vyvanse (lisdexamfetamine dimesylate). This phase IV clinical study is created by eHealthMe based on reports submitted to eHealthMe, and is updated regularly.

What is Vyvanse?

Vyvanse has active ingredients of lisdexamfetamine dimesylate. It is often used in attention deficit hyperactivity disorder. eHealthMe is studying from 35,870 Vyvanse users. Check the latest studies of Vyvanse.

What is Urinary incontinence aggravated?

Urinary incontinence aggravated (severe inability to control the flow of urine and involuntary urination) is found to be associated with 1,401 drugs and 555 conditions by eHealthMe. Check the latest studies of Urinary incontinence aggravated.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 22, 2026

15 people who have Urinary incontinence aggravated while taking Vyvanse were studied.

Could Vyvanse cause Urinary incontinence aggravated?

Severity of Urinary incontinence aggravated *:

least: 20.0 %
moderate: 53.33 %
severe: 26.67 %
most severe: 0.0 %

When people recovered from Urinary incontinence aggravated *:

while on drug: 0.0 %
after off the drug: 0.0 %
not yet: 100 %

Effectiveness of Vyvanse *:

not at all: 0.0 %
somewhat: 0.0 %
moderate: 30.77 %
high: 46.15 %
very high: 23.08 %

Race of the people *:

African American, Non-Hispanic: 10 %
American Indian/Alaska Native: 0.0 %
Asian: 0.0 %
Hispanic: 0.0 %
Native Hawaiians/Pacific Islanders: 0.0 %
Two or more races: 20 %
White, Non-Hispanic: 70 %

Time on Vyvanse *:

Gender of people when taking Vyvanse *:

female: 60 %
male: 40 %

Age of people when taking Vyvanse *:

Conditions people have *:

Asthma: 2 people, 13.33%
Stress And Anxiety: 2 people, 13.33%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 2 people, 13.33%
Weight Loss: 1 person, 6.67%
Mood Disorder (a condition characterized by distorted, excessive or inappropriate moods or emotions): 1 person, 6.67%
Bipolar I Disorder (mood disorder that is characterized by at least one manic or mixed episode): 1 person, 6.67%
Birth Control: 1 person, 6.67%
Hashimoto's Encephalopathy (chronic lymphocytic thyroiditis): 1 person, 6.67%
Insulin Resistance: 1 person, 6.67%
Multiple Allergies (allergy to multiple agents): 1 person, 6.67%

Other drugs people take besides Vyvanse *:

Lamictal: 3 people, 20.00%
Wellbutrin Sr: 3 people, 20.00%
Wellbutrin: 3 people, 20.00%
Abilify: 2 people, 13.33%
Adderall: 2 people, 13.33%
Clonazepam: 2 people, 13.33%
Cymbalta: 2 people, 13.33%
Escitalopram: 1 person, 6.67%
Ibuprofen: 1 person, 6.67%
Hydrocodone Bitartrate And Acetaminophen: 1 person, 6.67%

Other side effects people have besides Urinary incontinence aggravated *:

Weight Loss: 2 people, 13.33%
Dizziness: 2 people, 13.33%
Vision Problems: 2 people, 13.33%
Urinary Urgency: 2 people, 13.33%
Arthritis (form of joint disorder that involves inflammation of one or more joints): 1 person, 6.67%
Aura: 1 person, 6.67%
Breast Cyst: 1 person, 6.67%
Chronic Fatigue Syndrome (disorder that causes extreme fatigue): 1 person, 6.67%
Confusion: 1 person, 6.67%
Csf Leak: 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Vyvanse and have Urinary incontinence aggravated?

Check whether Urinary incontinence aggravated is associated with a drug or a condition

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Related studies

Urinary incontinence aggravated in Vyvanse

How the study uses the data?

The study is based on lisdexamfetamine dimesylate (the active ingredients of Vyvanse). Other drugs that have the same active ingredients (e.g. generic drugs) are considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.